Gilead shares surge on Letairis approval

Shares of Gilead Sciences surged in pre-market trading in response to the news that the FDA has approved its new therapy for pulmonary arterial hypertension. Some analysts applauded the move, noting that the approval marked Gilead's entry into the lucrative cardiovascular space. Interestingly, Gilead is taking a notably conservative approach in marketing Letairis. It will only allow someone to gain a prescription for the drug after the have taken an education course into risk factors such as liver damage and birth defects.

- see this release for more
- read the AP report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.